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talization, [3] [4] [5] [6] without significantly affecting platelet engraftment. 7 In a recently published study of Schriber et Its pharmacological application is reported to shorten chemotherapy-induced neutropenia as well as time to al 8 G-CSF support in the allogeneic BMT setting proved to significantly reduce the time to an absolute neutrophil engraftment in patients after bone marrow transplantation (BMT). In order possibly to establish further count у500/l, independent from GVHD prophylaxis or type of marrow donor (sibling vs matched unrelated donor), rationale for G-CSF treatment strategies in patients undergoing BMT, we evaluated G-CSF plasma levels of and without increased incidence of GVHD in matched unrelated BMT recipients. The observation, however, of a 89 patients after allogeneic BMT for chronic myeloid leukemia (CML). EDTA anti-coagulated plasma higher early mortality in patients receiving matched unrelated BMT and G-CSF support led to the suggestion that samples were collected starting on day ؊ ؊ ؊1 (before grafting) and thereafter twice weekly for four consecurandomized controlled clinical trials using G-CSF after allo-BMT and evaluation of the endogenous G-CSF plasma tive weeks. G-CSF levels were estimated by enzyme immunoassay. Patients with late (Ͼ Ͼ Ͼ30 days) bone marlevel courses after allo-BMT in order to improve our understanding of hemopoietic regulation mechanisms should be row engraftment had consistently higher G-CSF levels at day +1 (after grafting) compared to patients with performed. 8 In this paper we study the role of G-CSF plasma levels early (р р р30 days) engraftment, while all patients had low plasma levels on day ؊ ؊ ؊1/0. Mean G-CSF plasma levels of 89 patients undergoing allo-BMT for CML in relation to their clinical transplantation data, ie age, sex, state of and time to engraftment were correlated (r = 0.79). In univariate analyses, high G-CSF levels at days +1, +4, disease, conditioning regimen, type of marrow donor, degree of acute GVHD, and as predictors of engraftment. +7, +10 and several clinical variables (such as TBI, unrelated donor transplant, state of disease) were predictive of late engraftment. Further analysis by multivariate Cox regression resulted in the following predicMaterials and methods tive model: high G-CSF plasma levels at day +7 and +10 (after grafting), in combination with a blastic phase of Patients the disease were highly predictive of late engraftment. Table 1 summarizes characteristics of patients 1-86.
The significantly higher G-CSF levels in patients with
Patients 87-89 received G-CSF in pharmacological doses impaired engraftment may reflect early compensating (Neupogen 10 g/kg/24 h; Amgen, Munich, Germany) mechanisms of the hemopoietic system, which should be therapeutically and were considered separately. investigated further. Keywords: G-CSF; plasma levels; bone marrow transplantation; CML Samples
Five hundred and six EDTA anti-coagulated plasma samples were collected from the 89 patients with CML Granulocyte colony-stimulating factor (G-CSF) is constarting at day Ϫ1 (before grafting) and thereafter twice sidered to be a potent hemopoietic growth factor with priweekly for up to 5 consecutive weeks, depending on the mary effects on proliferation, differentiation and activation hematopoietic regeneration. of cells of the granulocyte lineage.
1,2 Particularly in BMT and after high-dose chemotherapy its therapeutic appli-ELISA The general outcome with a survival rate of 55.8% (median 
G-CSF levels post-BMT
thrombocyte engraftment (у20 000/l): range 10-89; mean 21 Ϯ 7
The time course of mean G-CSF plasma levels of all 86
Transplant-related mortality (survival Ͻ100 days):
patients is depicted in Figure 1 . Low G-CSF concentrations 16 (18.6%) could be found around the day of BMT, but already at day Outcome: 48 (55.8%) alive (median follow-up 46.2 months)
+1 after BMT levels increased with a peak at day +10 post-38 (55.8%) dead (median survival 13.5 months)
BMT, followed by declining levels. The mean G-CSF level was 469 Ϯ 1364 pg/ml (range from 50 to 23 215 pg/ml, median 146 pg/ml). Since none of the patients in our series had engraftment (defined as granulocyte count у500/l and with any other growth factors or cytokines, such as GMthrombocyte count у20 000/l (transfusion-independent)) CSF, M-CSF, IL-1 to IL-9 or other related substances.
between days 31 and 33 we arbitrarily chose to distinguish those with an early engraftment (р30 days, group A) from Statistics those with late engraftment (Ͼ30 days, group B) and compared the G-CSF profiles between these two groups, as Student's t-test was used for comparison of G-CSF levels. depicted in Figure 1 as well. The method of Kaplan and Meier was used to estimate engraftment-free survival, ie the time after BMT without functional hematological recovery (defined as 'days with a G-CSF and engraftment granulocyte count below 500/l and transfusionindependent thrombocyte count below 20 000/l'). For this Patients with late engraftment (n = 14, group B) presented higher G-CSF peaks at day 10 (mean 1582 pg/ml vs 467 analysis, the markers were divided into approximate terciles, or analyzed in a dichotomous fashion with the catepg/ml) than patients with early engraftment (n = 67, group A) (P Ͻ 0.001). While both groups started with identically gories absent or present. For comparison of Kaplan-Meier curves, log-rank statistics were calculated. Cox's prolow G-CSF levels at the day of BMT (mean 57 vs 62 pg/ml), already at day +1 after BMT values differed sigportional hazards model was used to assess the predictive value of the covariates singly and in combination nificantly (mean 356 vs 107 pg/ml, P Ͻ 0.001). Similar relations could be found on consecutive days until day +10, (independent variables) with engraftment as the dependent variable. Generally, the covariates were treated as continubut thereafter statistical differences disappear. The exponential regression curve between the mean Gous variables (age, G-CSF plasma levels at day Ϫ1/0, 1, 4, 7 and 10) or as categorical variables (state of disease CSF plasma levels over the investigated time and time to engraftment is shown in Figure 2 , and reveals a significant (first chronic phase, second chronic phase, and blastic phase), conditioning regimen (with/without TBI), grade of association (P Ͻ 0.01). Calculation of the exponential cor- relation in this setting gave an r-value of 0.79 between time Patient 8, the one with the latest engraftment of all (day +120), presented a completely different course. In this case to engraftment and mean G-CSF plasma levels (Figure 2 ).
In patients with early engraftment G-CSF levels were there was no G-CSF peak and after an abrupt increase at day 4, only slightly decreasing G-CSF values down to the inversely correlated with the absolute leukocyte count (WBC), as shown for four patients in Figure 3 . sensitivity of our assay (50 pg/ml) could be documented. The G-CSF profiles of two other patients (Nos 9 and 10) A G-CSF peak could be found regularly at the point of the leukocyte nadir between day +7 and +10 and then with low G-CSF plasma levels and late engraftment (day +37 and +52) are shown in the next table. declined by the time the granulocyte count rose. Around day +20 G-CSF plasma levels were in the range of the Three patients had to be left out of comparative considerations because they had received G-CSF therapeutically in sensitivity of the assay (50 pg/ml).
In patients with very late engraftment (Ͼ30 days, in order to shorten the phase of neutropenia. It is remarkable that one of these patients presented very high endogenous these cases between day 53 and 120 post-allo-BMT) the time course of G-CSF plasma levels appeared to be more G-CSF levels (7633 pg/ml) already 1 day before treatment with recombinant G-CSF. In this patient G-CSF levels heterogeneous (Figure 4) .
Two of the patients (Nos 5 and 6) also had a peak around could be increased to values higher than 25.000 pg/ml; the patient did not show any major hematological response, day 10, but had persistently increased G-CSF values thereafter, leading to much higher G-CSF plasma concentrations however, and died of bacterial sepsis 4 days later. than found in early engrafting patients. In a third patient Univariate analysis (No. 7) an extremely high G-CSF peak with values more than 3000 pg/ml could be found, followed by a fast
In order to detect predictors of engraftment for the other patients, Kaplan-Meier plots were calculated in an univaridecrease to less than 50 pg/ml. ate analysis. The results of these univariate calculations are around the day of BMT (mean 59 pg/ml), increasing already at day +1 (after grafting, mean 193 pg/ml), and depicted in Table 2 .
In summary, high G-CSF levels at days +1, +4, +7 and peaking at day +10 (mean 1012 pg/ml). This peak was followed by a slow decrease until day 28 (mean 202 pg/ml) +10 were predictive of late engraftment. In addition, the following clinical transplantation variables (patient in most of our patients (Figure 1 ). G-CSF levels found in our study at day Ϫ1 (before received TBI as conditioning regimen, transplanted with a matched unrelated donor, or transplanted in blastic phase) grafting) and at day of BMT are comparable to the values described for healthy persons by Kawakami et al 9 (mean were predictive of late engraftment.
25.3 pg/ml, range 20-95 pg/ml) and Watari et al 10 (mean 33 pg/ml, range 30-263 pg/ml) and to levels described for Multivariate analysis CML patients by Saitoh et al 11 (2.95 Ϯ 3.91 pg/ml) detected with a more sensitive assay. In order to evaluate further these predictors of engraftment, we calculated proportional hazard models to assess the preAlready by day +1 G-CSF levels in our study increased to values much higher than found in healthy persons. In dictive value in uni-and multivariate analysis (Table 3) . Again, all variables except sex, age, and the G-CSF plasma the bone marrow transplant setting (heterogeneous patient group, different diagnoses, autologous and allogeneic level at day Ϫ1/0 proved to be significant single predictors of engraftment. As illustrated by the 2 log-likelihood esti-BMT), similar values (range between 20 and 2552 pg/ml G-CSF) and courses, even with a similar peak between day mates, the model including G-CSF at day +7, day +10 and the state of disease was the best predictive model. Com-7 and 10, were reported by Cairo et al 12 and Papadakis et al. 13 Comparable courses and values with increasing levels pared with this model, the full model with all markers included did not add significant information.
at day +1 (after grafting) are described in the autologous peripheral blood stem cell transplant (PBSCT) setting by Kawano et al, 14 Baiocchi et al, 15 Haas et al, 16 Miksits et al 17 and Uchiyama et al. 18 However, the peak in the PBSCT Discussion studies occurred earlier, ie between day 3 and 7.
The inverse relationship between circulating G-CSF levThe time course of G-CSF plasma levels in our series (allo-BMT for CML (Figure 1) ) was characterized by low values els and degree of neutropenia (Figures 3 and 4) confirmed 14 Haas et al, 16 Miksits et G-CSF and failed to engraft. Three similar courses are depicted in Figure 4 (patients 8-10), although these courses al 17 and Uchiyama et al 18 although direct comparison between allo-BMT and auto-PBSCT is difficult. The main were unusual in our study (only three patients out of 86).
In most of our cases, patients with late engraftment or faildifference to our series was, that in our study this finding was limited to patients with early engraftment, while ure to engraft had consistently higher G-CSF levels than patients with early engraftment (Figure 3) . It is remarkable patients with late engraftment presented changes in their G-CSF plasma levels that could not be correlated to the that this difference had already become significant at day +1 (after grafting), while both groups presented nearly WBC exclusively. The overall graft function or other clinical influences like severe infections may have influence on identical G-CSF levels at day Ϫ1 or 0 (before or at grafting) (Figure 2 ). Cairo et al 12 reported high G-CSF levthe regulation of the endogenous G-CSF production as well. els in patients with poor graft function as well, but that before the institution of G-CSF support. In order to further establish a rationale for G-CSF support this could prove study represented a very heterogeneous and small patient group, complicating statistical evaluation. Papadakis et al 13 whether the clinical benefit of therapeutic G-CSF is limited to those patients with low endogenous G-CSF levels or in contrast, found no association in prospective evaluation of 36 recipients of T cell-depleted allo-BMT between Gwhether pharmacological doses of G-CSF will result in improved marrow recovery despite high levels of endogen-CSF kinetics within 1 month post-transplant and the development of primary non-engraftment or secondary graft failous G-CSF. ure, but they also observed an inverse relationship between G-CSF and concomitant WBC levels.
Kaplan-Meier plots (univariate analysis, Results, see
